Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Capital Expenditures
Editas Medicine Inc
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Capital Expenditures
$-4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
$-777m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
$-585m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-12%
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
$-1.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
$-258.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-18%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
$-926.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-19%
|
See Also
What is Editas Medicine Inc's Capital Expenditures?
Capital Expenditures
-4m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Capital Expenditures amounts to -4m USD.
What is Editas Medicine Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
3%
Over the last year, the Capital Expenditures growth was 2%. The average annual Capital Expenditures growth rates for Editas Medicine Inc have been 17% over the past three years , 3% over the past five years .